港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫美概念股

890.084

-9.556-1.06%

漲家數：4

跌家數：6

平家數：3

市盈率：- -

高：909.125

開：899.442

低：887.730

收：899.640

成交量：3,244.44萬

成交額：3.14億

市值：1,480.93億

流通市值：1,090.74億

資料載入中...

總覽新聞資訊

Lazard Asset Management LLC增持康哲藥業(00867.HK)126.5萬股每股作價約10.95港元

復星醫藥：9月15日回購130萬股股份

復星醫藥(02196.HK)周二回購130萬股涉2,207萬元

阿斯达克财经

現代牙科(03600)股價上升6.191%，現價港幣$7.89

阿斯达克财经

康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書

康哲藥業CMS-D001獲國家藥監局藥物臨床試驗批准通知書——2026年9月11日

三生製藥(01530)9月14日斥資309.4萬港元回購20萬股

復星醫藥(02196)9月14日斥資2470.51萬港元回購145.5萬股

復星醫藥(02196)股價上升5.021%，現價港幣$17.15

阿斯达克财经

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

《股市簡訊》復星醫藥H股升2.5%，地舒單抗生物類似藥HLX14的註冊申請獲受理

雲南瑞麗產業協作園區隴川片區交出亮眼「成績單」

時代天使(06699)授出合共156.39萬份受限制股份單位

智通财经网

復星醫藥(02196.HK)周五斥2,186萬元回購134萬股

阿斯达克财经

復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理

復星醫藥(02196)9月11日斥資約2186.42萬港元回購134萬股

昊海生物科技：9月11日斥資40萬港元回購24300股

南方财经网

瑞麗醫美(02135)股價下跌6.612%，現價港幣$0.113

阿斯达克财经

【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善

【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1593/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":890.084,"timestamp":1789459707407,"preClose":899.6395,"halted":0,"volume":32444447,"delay":0,"changeRate":-0.010622,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-9.555542,"latestTime":"09-15 16:00:00","open":899.4419,"high":909.12524,"low":887.7295,"amount":314217393,"amplitude":0.023783,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":1.147457,"peRate":10.486004,"turnoverRate":0.001531,"increases":3,"decrements":7,"flats":3,"marketCap":148092540760,"floatMarketCap":109073626840},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":909.12524,"amplitude":0.023783,"preClose":899.6395,"low":887.7295,"pbRate":"1.147457","latestPrice":890.084,"volume":32444447,"delay":0,"open":899.4419,"prevYearClose":1094.978,"prevWeekClose":869.902,"prevMonthClose":902.195,"prevQuarterClose":846.145,"fiveDayClose":918.391,"twentyDayClose":944.095,"sixtyDayClose":833.357,"secType":"PLATE","market":"HK","turnoverRate":0.001531,"peRate":10.486004,"marketCap":148092540760,"floatMarketCap":109073626840,"timestamp":1789459707407,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667418916","title":"Lazard Asset Management LLC增持康哲藥業(00867.HK)126.5萬股 每股作價約10.95港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667418916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667418916?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:53","pubTimestamp":1789469628,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BMCWC346.EUR","00867","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","SG9999015986.USD","LU2488822045.USD","SG9999004220.SGD","SG9999015978.USD","SG9999015952.SGD","BK1593","SG9999015945.SGD","IE00BVYPNQ40.USD","IE00BYV24P56.USD","BK1191","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667936645","title":"復星醫藥：9月15日回購130萬股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667936645","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667936645?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:58","pubTimestamp":1789466293,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1593","02196","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645208","title":"復星醫藥(02196.HK)周二回購130萬股 涉2,207萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645208","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:49","pubTimestamp":1789465740,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，于9月15日回购130万股，每股作价介乎16.89至17.1元，涉资约2,207.07万元。(da)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-15 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544591/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544591/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0175","BK0183","BK0187","BK1191","BK0096","BK0188","600196","BK0196","02196","BK1515","BK1593","BK0012","BK0060","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667613354","title":"現代牙科(03600)股價上升6.191%，現價港幣$7.89","url":"https://stock-news.laohu8.com/highlight/detail?id=2667613354","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667613354?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 11:15","pubTimestamp":1789442100,"startTime":"0","endTime":"0","summary":"[上升股]现代牙科(03600) 股价在上午11:14比前收市价上升6.191%，现股价为港币$7.89。至目前为止，今日最高价为$7.89，而最低价为$7.43。总成交量为2.9万股，总成交金额为港币$21.823万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151426/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151426/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03600","BK1583","BK1593","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657414","title":"康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年9月11日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于2026年9月14日收到药物临床试验批准通知书。NMPA同意集团开展临床试验以评价CMS-D001治疗系统性红斑狼疮适应症的有效性和安全性。CMS-D001作为高选择性TYK2抑制剂，相较于泛JAK抑制剂，CMS-D001对其他JAK家族激酶的影响较小，可在长期疾病控制中维持疗效并降低相关安全风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BYV24P56.USD","IE00BVYPNQ40.USD","BMED","SG9999004311.SGD","PSYK","BK1161","LNGR","IBBJ","SG9999015986.USD","LU2488822045.USD","159992","00867","06978","IE00BMCWC346.EUR","SG9999015945.SGD","SG9999015952.SGD","BK1574","BK1593","IE00BVYPNP33.GBP","IBBQ","MEDX","BK1191","SG9999004220.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170124235","title":"康哲藥業CMS-D001獲國家藥監局藥物臨床試驗批准通知書——2026年9月11日","url":"https://stock-news.laohu8.com/highlight/detail?id=1170124235","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170124235?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:22","pubTimestamp":1789381329,"startTime":"0","endTime":"0","summary":"2026年9月11日，康哲药业（CMS）宣布其核心在研产品CMS-D001已正式获得国家药品监督管理局（NMPA）颁发的药物临床试验批准通知书。这一里程碑式进展标志着该药物进入临床开发阶段的关键一步。据悉，CMS-D001有望为相关疾病领域带来全新治疗选择，进一步丰富公司的创新产品管线。此次获批不仅凸显了康哲药业在药物研发领域的持续投入与扎实积累，也为其后续推进临床试验、加速产品上市奠定了坚实基础。市场人士普遍认为，这一利好消息或将对公司股价及长期战略布局产生积极影响，值得投资者密切关注。康哲药业表示，将严格按照国家相关法规和伦理要求，高效推进后续临床研究工作，力争早日惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYV24P56.USD","IE00BVYPNQ40.USD","SG9999015952.SGD","IE00BVYPNP33.GBP","LU2488822045.USD","BK1593","BK1191","SG9999015945.SGD","IE00BMCWC346.EUR","SG9999015978.USD","SG9999015986.USD","00867","SG9999004220.SGD","SG9999004311.SGD","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576906","title":"三生製藥(01530)9月14日斥資309.4萬港元回購20萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576906","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667576906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:15","pubTimestamp":1789380928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月14日，该公司斥资309.4万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1583","BK1161","BK1593","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667575016","title":"復星醫藥(02196)9月14日斥資2470.51萬港元回購145.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667575016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667575016?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:12","pubTimestamp":1789380740,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月14日，该公司斥资2470.51万港元回购145.5万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0060","02196","BK0183","BK0187","BK1593","BK0239","BK0012","BK1191","BK0196","600196","BK0096","BK0175","BK1515","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667353659","title":"復星醫藥(02196)股價上升5.021%，現價港幣$17.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2667353659","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667353659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:59","pubTimestamp":1789372740,"startTime":"0","endTime":"0","summary":"[上升股]复星医药(02196) 股价在下午03:58比前收市价上升5.021%，现股价为港币$17.15。至目前为止，今日最高价为$17.15，而最低价为$16.12。总成交量为571.7万股，总成交金额为港币$9.677千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141758/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141758/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["600196","BK0183","BK0239","BK1593","BK0187","BK1515","02196","BK0012","BK0060","BK0028","BK0175","BK0196","BK1191","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","KCAI","LU0634319403.HKD","06978","LU1961090484.USD","IBBQ","KURE","159992","BK4588","LU0348767384.USD","01177","LU0348735423.USD","LU0455707207.USD","LU2476274308.USD","LU0607220059.USD","BK1593","LU0348784397.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0417516738.SGD","01801","LU2097828805.USD","LU2097828714.EUR","HK0000165453.HKD","LU0348827113.USD","MEDX","LU2476274720.SGD","09969","LNGR","LU1831875114.USD","09926","LU0244354667.USD","LU1188198961.HKD","LU0348825331.USD","LU2097828557.USD","BK1574","LU0326950275.SGD","LU1969619763.USD","BK1191","LU0348766576.USD","01530","BK1161","IE00BZ08YR35.GBP","BK1521","LU2242644610.SGD","LU2778985437.USD","BK1589","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667310766","title":"《股市簡訊》復星醫藥H股升2.5%，地舒單抗生物類似藥HLX14的註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667310766","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667310766?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:30","pubTimestamp":1789353058,"startTime":"0","endTime":"0","summary":"《股市简讯》复星医药H股升2.5%，地舒单抗生物类似药HLX14的注册申请获受理* 中国复星医药H股2196.HK周一早盘一度升2.5%，其A股600196.SS涨1.5%，地舒单抗生物类似药HLX14的注册申请获受理。* 该公司此前公告称，控股子公司--上海复宏汉霖及其控股子公司自主研发的地舒单抗生物类似药HLX14 120mg/瓶规格的药品注册申请获国家药品监督管理局受理。* 复星医药H股今年迄今大跌14.4%，同期A股挫近两成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4T45604K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0187","BK0028","BK0196","BK0188","BK1515","BK1593","BK0096","BK0175","BK0239","BK0012","BK0060","02196","BK0183","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666060135","title":"雲南瑞麗產業協作園區隴川片區交出亮眼「成績單」","url":"https://stock-news.laohu8.com/highlight/detail?id=2666060135","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666060135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 16:32","pubTimestamp":1789201920,"startTime":"0","endTime":"0","summary":"2026年上半年，云南瑞丽产业协作园区陇川片区党工委、管委会以务实之举答好“招得来、留得住、发展好”这一课题，推动区域发展从“过路地”变“聚宝盆”。依托凯喜雅、德宏正信等龙头企业，园区集聚服装轻纺及关联企业9家，茧丝绸全产业链格局初步形成。截至7月底，陇川片区企业用工人数从8046人增至9291人，净增1245人。从通道到引擎，从蓝图到实景，陇川片区正以实干实效回应各方期待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-12/doc-inirqfia5206901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666852414","title":"時代天使(06699)授出合共156.39萬份受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666852414","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666852414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 20:27","pubTimestamp":1789129651,"startTime":"0","endTime":"0","summary":"时代天使(06699)发布公告，于2026年9月11日，本公司董事会决议根据首次公开发售后受限制股份单位计划向16名承授人(承授人)授予合共156.39万份受限制股份单位。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg41.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg41.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1593","06699","BK1583","BK1587","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666258523","title":"復星醫藥(02196.HK)周五斥2,186萬元回購134萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666258523","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666258523?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:49","pubTimestamp":1789120140,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，于9月11日回购134万股，每股作价介乎16.14至16.5元，涉资约2,186.42万元。(da)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-11 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250731211503309_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250731211503309_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544114/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544114/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["600196","02196","BK0239","BK1191","BK0175","BK0188","BK0096","BK1515","BK0183","BK1593","BK0012","BK0060","BK0028","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666235705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0096","BK0188","BK1515","BK4585","LU2272731782.SGD","XPH","BK0196","BK1593","IBB","LU1992135399.USD","BK4588","BK0187","LU2322448791.USD","BK1191","LU2272731865.HKD","LU2322448957.HKD","BK0060","BK0012","LU2272731600.USD","PPH","BK0183","LU2473716301.USD","600196","IE00B5TLWC47.USD","BK0028","LU1992135472.HKD","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528460","title":"復星醫藥(02196)9月11日斥資約2186.42萬港元回購134萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528460","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528460?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:36","pubTimestamp":1789119362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月11日该公司斥资约2186.42万港元回购134万股，回购价格为每股16.14至16.5港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0239","600196","BK0028","BK0060","BK0183","02196","BK0196","BK0175","BK1191","BK0188","BK0012","BK1593","BK1515","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666404595","title":"昊海生物科技：9月11日斥資40萬港元回購24300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666404595","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666404595?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:06","pubTimestamp":1789117560,"startTime":"0","endTime":"0","summary":"南财智讯9月11日电，昊海生物科技（06826.HK）发布翌日披露报表，公司于2026年9月11日在香港联合交易所进行股份回购，回购股份数量为24300股，每股最高回购价16.68港元，每股最低回购价16.31港元，付出的总代价为399865港元。回购股份拟注销，未持作库存股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113872133540.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113872133540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06826","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666543626","title":"瑞麗醫美(02135)股價下跌6.612%，現價港幣$0.113","url":"https://stock-news.laohu8.com/highlight/detail?id=2666543626","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666543626?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:55","pubTimestamp":1789098900,"startTime":"0","endTime":"0","summary":"[下跌股]瑞丽医美(02135) 股价在上午11:54比前收市价下跌6.612%，现股价为港币$0.113。至目前为止，今日最高价为$0.116，而最低价为$0.113。总成交量为2万股，总成交金额为港币$2290。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112418/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112418/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02135","BK1209","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666127155","title":"【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2666127155","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666127155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:18","pubTimestamp":1789089493,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，医疗器械板块Q2收入延续增长趋势，单季度利润增速四年来首次转正。该机构认为，随着集采影响逐步出清叠加创新驱动和海外业务加速的双重助力，医疗器械板块业绩有望逐步改善。尽管季度业绩增速可能有所波动，Q3能否相比Q2加速尚不确定，但大趋势来看，26和27年年度业绩持续改善的确定性较强。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991348","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01066","09996","BK1617","BK1591","BK1583","01302","HART","BK1161","LNGR","BK1189","LU0287142896.SGD","02252","BK1571","RSPH","BK1615","BK1100","02190","02235","06826","BK1247","GDOC","BK1585","601066","BK1589","BK1600","LGHT","BK1587","BK1515","IEIH","PTH","AGNG","BK1501","00241","BK1610","BK0276","KCE","LU0173614495.USD","HK0000165453.HKD","BK1584","00853","MDEV","MEDX","BK1142","BK1222","BK1502","BK1593","159883","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666917512","title":"【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666917512","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666917512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:07","pubTimestamp":1789088866,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年上半年，CXO板块及生命科学上游板块整体业绩表现稳健，行业进入复苏阶段。上半年海外投融资景气度持续，美联储加息预期走弱，早研板块整体的景气度持续走强，AIDD的快速发展也将进一步催化未来相关实验和验证需求的爆发，该机构认为CRO板块有望量价齐升。CDMO板块上半年龙头业绩表现稳健，整体订单增速持续加快，行业景气度回升。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU1997244956.HKD","BK1574","LU2328871848.SGD","06030","09688","BK0028","BK1500","02228","LU1997245177.USD","SG9999014674.SGD","01530","06821","BK1100","LU0634319403.HKD","600030","LU0348827113.USD","CXO","LU0348783233.USD","BK0188","LU1794554557.SGD","SG9999004311.SGD","01789","LU0463099449.HKD","LU2778985437.USD","BK0196","WX","02196","02367","LU1188198961.HKD","01099","BK1593","LU2476274308.USD","LU1969619763.USD","LU1997245094.SGD","LU0244354667.USD","LU0561508036.HKD","LU1146622755.USD","LU2495084118.USD","09926","LU0417516902.SGD","LU0405327494.USD","KCE","KURE","LU0540923850.HKD","03933","BK1521","IE00B3M56506.USD","02268","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}]}}